US Stock MarketDetailed Quotes
SLDB Solid Biosciences
- 8.1100
- -0.4000-4.70%
Close Sep 6 16:00 ET
- 8.1100
- 0.00000.00%
Post 16:02 ET
313.01MMarket Cap-2465P/E (TTM)
8.6483High7.9500Low151.25KVolume8.5100Open8.5100Pre Close1.23MTurnover0.95%Turnover RatioLossP/E (Static)38.60MShares15.050052wk High1.62P/B128.73MFloat Cap1.810052wk Low--Dividend TTM15.87MShs Float822.6000Historical High--Div YieldTTM8.21%Amplitude1.8100Historical Low8.1330Avg Price1Lot Size
Solid Biosciences Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 21.84%-21.47M | 10.01%-25.19M | 3.88%-94.18M | 39.61%-20.82M | 12.39%-17.9M | -72.98%-27.47M | -2.96%-28M | -25.99%-97.98M | -65.18%-34.48M | -10.88%-20.43M |
| Net income from continuing operations | -1.80%-25.07M | 19.18%-24.3M | -11.67%-96.02M | -34.22%-20.34M | -2.79%-20.98M | 1.85%-24.63M | -18.72%-30.07M | -19.11%-85.98M | 18.59%-15.15M | -13.50%-20.41M |
| Operating gains losses | ---- | ---- | --374K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 75.68%1.24M | -69.64%327K | 7.18%2.58M | -60.48%213K | 34.25%588K | -2.63%703K | 51.90%1.08M | -18.76%2.41M | -29.08%539K | -41.68%438K |
| Other non cash items | --1.24M | ---94K | ---- | ---- | ---- | ---- | ---- | -22,720.99%-18.49M | ---18.24M | --0 |
| Change In working capital | 101.17%78K | -142.32%-2.19M | -71.78%-6.34M | 36.77%-1.86M | 257.89%3.1M | -198.52%-6.67M | 83.71%-905K | 83.99%-3.69M | 58.09%-2.94M | 61.80%-1.96M |
| -Change in receivables | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 200.00%110K | --0 | --0 |
| -Change in prepaid assets | 87.99%-219K | -206.03%-1.34M | -7.01%3.44M | -68.53%124K | 42.73%3.88M | -146.15%-1.82M | 137.46%1.26M | 139.96%3.7M | 105.18%394K | 220.13%2.72M |
| -Change in payables and accrued expense | 128.80%1.16M | 60.48%-856K | -1,767.75%-9.77M | 40.52%-1.99M | 66.00%-1.59M | -144.91%-4.03M | -479.14%-2.17M | 156.02%586K | -206.07%-3.34M | -814.35%-4.68M |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 36.07%-8.08M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 21.84%-21.47M | 10.01%-25.19M | 3.88%-94.18M | 39.61%-20.82M | 12.39%-17.9M | -72.98%-27.47M | -2.96%-28M | -25.99%-97.98M | -65.18%-34.48M | -10.88%-20.43M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 89.27%-5.18M | -203.30%-38.49M | -83.62%9.69M | -31.47%45.3M | -265.24%-24.64M | 19.07%-48.23M | -1.28%37.26M | 164.95%59.16M | 119.05%66.1M | 120.56%14.91M |
| Net PPE purchase and sale | 46.64%-286K | 70.55%-149K | 37.27%-1.52M | 89.49%-90K | -60.25%-383K | 52.82%-536K | -175.00%-506K | -88.52%-2.42M | -29.70%-856K | -0.84%-239K |
| Net business purchase and sale | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --31.52M | ---- | ---- |
| Net investment purchase and sale | 89.75%-4.89M | -201.54%-38.35M | -62.71%11.2M | 28.09%45.39M | -260.10%-24.25M | 18.41%-47.7M | -0.42%37.77M | 133.46%30.05M | 14.91%35.43M | 120.96%15.15M |
| Net other investing changes | --0 | --5K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 89.27%-5.18M | -203.30%-38.49M | -83.62%9.69M | -31.47%45.3M | -265.24%-24.64M | 19.07%-48.23M | -1.28%37.26M | 164.95%59.16M | 119.05%66.1M | 120.56%14.91M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 91.06%5M | 107.24M | -95.83%3.12M | -99.32%505K | 0 | 3,484.93%2.62M | 0 | -44.56%74.83M | 113,137.88%74.74M | -133.33%-1K |
| Net issuance payments of debt | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --2.08M | ---- | ---- |
| Net common stock issuance | 110.99%5.36M | --111.92M | -95.90%2.97M | -99.40%435K | --0 | --2.54M | --0 | -46.21%72.55M | --72.55M | --0 |
| Proceeds from stock option exercised by employees | 97.44%154K | --151K | -27.09%148K | -35.78%70K | --0 | 6.85%78K | --0 | 89.72%203K | 65.15%109K | -133.33%-1K |
| Net other financing activities | ---286K | ---4.83M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 91.06%5M | --107.24M | -95.83%3.12M | -99.32%505K | --0 | 3,484.93%2.62M | --0 | -44.56%74.83M | 113,137.88%74.74M | -133.33%-1K |
| Net cash flow | ||||||||||
| Beginning cash position | -28.28%119.41M | -51.76%75.85M | 29.71%157.22M | 0.02%50.87M | 65.66%93.4M | 26.33%166.48M | 29.71%157.22M | -21.84%121.21M | -54.52%50.86M | -72.19%56.38M |
| Current changes in cash | 70.38%-21.64M | 370.15%43.56M | -325.96%-81.37M | -76.51%24.98M | -670.37%-42.53M | 3.08%-73.08M | -12.39%9.27M | 206.34%36.01M | 1,035.32%106.36M | 93.93%-5.52M |
| End cash Position | 4.67%97.76M | -28.28%119.41M | -51.76%75.85M | -51.76%75.85M | 0.02%50.87M | 65.66%93.4M | 26.33%166.48M | 29.71%157.22M | 29.71%157.22M | -54.52%50.86M |
| Free cash flow | 22.31%-21.75M | 11.09%-25.34M | 5.24%-95.7M | 40.82%-20.91M | 14.05%-18.28M | -64.58%-28M | -4.12%-28.5M | -27.77%-100.99M | -64.09%-35.34M | -13.97%-21.27M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg